Amneal Pharmaceuticals (AMRX) is recalling three lots of Sulfamethoxazole/Trimethoprim tablets 400mg/80mg as the tablets may exhibit black spots on the tablet surface due to microbial contamination. The observance of black spots was reported in a product quality complaint, the FDA said on its website. The product is indicated for the treatment of Urinary tract infections.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals announces FDA approved Brekiya injection
- Amneal Pharmaceuticals Approves Key Proposals at Annual Meeting
- Amneal Pharmaceuticals, Apiject announce strategic collaboration
- Amneal Pharmaceuticals Reports Strong Q1 2025 Results
- Amneal Pharma’s Earnings Call Highlights Strong Growth